First Step of The New Guidelines Consultation Announced On October 25, 2023, the Patented Medicine Prices Review Board (PMPRB) released details on the first of its two-step consultation process for developing its new set of price regulatory guidelines. PMPRB will send invitations to stakeholders for ...
Private: Gallery Post #1
On November 10, 2023, the Patented Medicine Prices Review Board (PMPRB) launched first phase of its consultation process towards development of new price regulatory Guidelines. PMPRB published its Scoping Paper for the Consultations on the Board’s Guidelines and invited feedback to be provided either ...
On September 27, 2023, the Patented Medicine Prices Review Board (PMPRB) published its final decision regarding the Amended Interim Guidance first proposed on June 20, 2023.Effective immediately, the proposed amendments to the Interim Guidance are implemented without changes, notwithstanding the concerns raised by many of the ...
PDCI Strengthens Leadership to Enhance Real World Evidence (RWE) Services and Strategic Consulting Capabilities
Mississauga, ON - September 11, 2023 – Canada’s leading biopharmaceutical pricing and reimbursement consultancy, PDCI Market Access (PDCI), a division of McKesson Canada, today announced the appointment of three leaders, Nabil Tadros, Andrea Lau and John-Paul Dowson to further enhance the company’s capabilities in delivering high-quality services and ...
On September 5, 2023, the pan-Canadian Pharmaceutical Alliance (pCPA) announced the appointment of Douglas Clark as its first CEO, effective September 11, 2023. Clark was Executive Director of the Patented Medicine Prices Review Board (PMPRB) for almost a decade before he resigned from that position earlier this year....
PCPA Seeks Stakeholder Input On Its Proposed Process To Implement CADTH Time-Limited Recommendations
The pan-Canadian Pharmaceutical Alliance (pCPA) introduced its proposed pCPA Temporary Access Process (pTAP) and invited stakeholders’ input on the process, its principles and conditions by August 18th, 2023. The proposed pTAP and its associated principles are intended to inform pCPA negotiations and product listing agreements for ...
On June 6, 2023, the Patented Medicine Prices Review Board (PMPRB) released its first NEWSletter of 2023, providing updates on recent activities among the Board and Board staff. Updates from the NEWSletter and PDCI’s insights on potential implications are summarized below. Despite recent quietness from PMPRB on its ...
On June 5, 2023, the Canadian Agency for Drugs and Technologies in Health (CADTH) announced a series of process improvements it plans to explore or add to its drug reimbursement review process. These changes - aimed at gaining efficiencies, reducing timelines and improving transparency – include:...
On June 20, 2023, PMPRB published proposed amendments to the Interim Guidance relating to New Medicines. PMPRB has invited stakeholders to comment on the approach before August 21, 2023 (60-day consultation). After stakeholder consultation, a new set of guidelines is anticipated to be finalized in 2024....
PDCI’s Webinar Series: Tips for Health Technology Assessment (HTA) Submissions: Plan your Trip, Pack your Bags and Leave on Time
Join us on May 31st @ 12 p.m. ET for our upcoming webinar entitled: Tips for Health Technology Assessment (HTA) Submissions: Plan your Trip, Pack your Bags and Leave on Time. Join PDCI HTA Experts Andrea Lau (Associate Director, HTA and Clinical Evaluation), Tuhin Maity (Associate ...